Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?

Siu Wai CHOIa and Cyrus K. HOabc

aDepartment of Anesthesiology, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR; bFaculty of Veterinary and Agricultural Sciences, The University of Melbourne, Melbourne, Australia; cFaculty of Health and Social Sciences, School of Nursing, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR

ABSTRACT

Objectives: This is a narrative review, investigating the antioxidant properties of drugs used in the management of diabetes, and discusses whether these antioxidant effects contribute to, confound, or conceal the effects of antioxidant therapy.

Methods: A systematic search for articles reporting trials, or observational studies on the antioxidant effect of drugs used in the treatment of diabetes in humans or animals was performed using Web of Science, PubMed, and Ovid. Data were extracted, including data on a number of subjects, type of treatment (and duration) received, and primary and secondary outcomes. The primary outcomes were reporting on changes in biomarkers of antioxidants concentrations and secondary outcomes were reporting on changes in biomarkers of oxidative stress.

Results: Diabetes Mellitus is a disease characterized by increased oxidative stress. It is often accompanied by a spectrum of other metabolic disturbances, including elevated plasma lipids, elevated uric acid, hypertension, endothelial dysfunction, and central obesity. This review shows evidence that some of the drugs in diabetes management have both in vivo and in vitro antioxidant properties through mechanisms such as scavenging free radicals and upregulating antioxidant gene expression.

Conclusion: Pharmaceutical agents used in the treatment of type 2 diabetes has been shown to exert an antioxidant effect.

Introduction

The number of people worldwide with diabetes mellitus (DM) has increased from 30 million to 180 million since 1985 [1–3]. This increase is anticipated to continue, with the fastest increases seen in Asia [1,2,4]. Over 90% of diabetes is Type 2 DM, which is also associated with dyslipidemia, hypertension, and elevated plasma uric acid [3,5], which can lead to long term micro- and macro-vascular complications.

Owing to their various metabolic problems, most Type 2 DM subjects are commonly treated by a ‘polypharmacy’ of oral hypoglycemic agents, statins, fibrates, and anti-hypertensive drugs of various types [6]. Some of these have been reported to have pleiotropic effects and antioxidant properties [7–9]. Oxidative stress is increased in DM, and there is often a depletion of body stores of ascorbic acid (vitamin C), which is an important dietary-derived antioxidant. Antioxidant supplementation has been suggested as a potentially beneficial adjunct therapy [10,11]. In this article, we review the literature in relation to antioxidant effects of drugs used in the management of diabetes, and discuss results of antioxidant supplementation studies in DM patients from the perspective of the possible confounding or concealing influence of drug-induced antioxidant effects.

Type 2 DM and its management: a brief overview

Type 2 DM is a state of continuous or intermittent hyperglycemia caused by a relative deficiency of insulin. Tissues are insulin resistant and there may also be β-cell dysfunction or failure [12]. Hypoglycemic agents are aimed at improving insulin secretion and action, and limiting or slowing absorption of glucose in the gastrointestinal tract [13]. These drugs are taken orally, and may be combined with insulin injections for those patients who fail to respond acceptably to any of the oral hypoglycemic agents alone (Table 1).

Type 2 DM is often accompanied by a spectrum of other metabolic disturbances, including elevated plasma total and low density lipoprotein cholesterol (TC and LDL-C), low high density lipoprotein cholesterol (HDL-C), elevated triglycerides (Tg), elevated uric acid, hypertension, endothelial dysfunction, central obesity, and elevated inflammatory biomarkers (high sensitivity C-reactive protein (hsCRP) and inflammatory cytokines such as interleukin 6 (IL-6) [24]. The drugs most commonly used to treat dyslipidemia and hypertension in Type 2 DM patients are presented in Table 2.

Antioxidant effects of drugs used in the management of Type 2 DM

As noted, there is a polypharmacy armory for the management of patients with DM, and although many patients may be managed using dietary strategies alone, many patients with diabetes will be on a combination of several of these drugs. Many of these drugs exhibit pleiotropic effects, that is, beneficial effects separate from their primary action. As summarized in Table 3, in vitro studies, using the Ferric...
| Oral hypoglycemic agents used in type 2 DM. | Chemical name and formula | Chemical structure | Mechanism of primary action | Typical dosage/blood levels | C<sub>max</sub> & AUC of drug |
|-------------------------------------------|--------------------------|-------------------|-----------------------------|-----------------------------|-----------------------------|
| Metformin (Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet) | 3-(diaminomethylidene)-1,1-dimethylguanidine C<sub>6</sub>H<sub>11</sub>N<sub>5</sub> | ![Chemical structure](image) | Increases glucose transport across the cell membrane in skeletal muscle. Acts only in the presence of endogenous insulin | 500–850 mg daily. Maximum daily dose 2550 mg. | C<sub>max</sub> = 1713.54 ± 508.75 ng/ml; AUC = 9284.88 ± 2155.57 ng.h/ml [14] |
| Glipizide (Glucotrol) | N-[2-[(4-carboxamido)phenyl]ethyl]-5-methylpyrazine-2-carboxamide C<sub>17</sub>H<sub>27</sub>N<sub>5</sub>O<sub>4</sub>S | ![Chemical structure](image) | Binds to ATP-sensitive potassium-channel receptors on pancreatic cell surface, decreasing potassium conductance, and causing depolarization of membrane. This stimulates calcium ion influx through voltage-sensitive calcium channels, inducing secretion, or exocytosis, of insulin. | 5 mg administered 30 min before meals. Maximum dose 40 mg daily. | C<sub>max</sub> = 523 ± 60 ng/ml; AUC = 1897 ng.h/ml [15] |
| Glyburide/Glibenclamide (Micronase, Diabeta, Glynase Prestab) | 5-chloro-N-[2-[(4-carboxamido)phenyl]ethyl]-2-methoxy benzamide C<sub>23</sub>H<sub>28</sub>ClN<sub>3</sub>O<sub>5</sub>S | ![Chemical structure](image) | Same as glipizide. | 2.5–5 mg daily of regular tablets or 1.5–3 mg daily of micronized tablets. Maximum dose 1.25–20 mg of regular tablets and 0.75–12 mg of micronized tablets. | C<sub>max</sub> = 147.1 ± 23.6 ng/ml; AUC = 255.7 ± 28.1 ng.h/ml [16] |
| Tolbutamide (Orinase) | 1-butyl-3-(4-methylphenyl)sulfonylurea C<sub>9</sub>H<sub>13</sub>NO<sub>3</sub>S | ![Chemical structure](image) | Same as glipizide. | 500 mg. | C<sub>max</sub> = 63 ± 11 μg/ml; AUC = 721 ± 94 μg.h/ml [17] |
| Drug          | Chemical Structure | Description                                                                 | Typical Dose | Pharmacokinetic Parameters |
|--------------|--------------------|------------------------------------------------------------------------------|--------------|----------------------------|
| Nateglinide (Starlix) | (2S)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid C₁₉H₂₇NO₃ | Stimulates pancreas to produce insulin (similar to the sulfonylureas). Appears to have a faster onset and a shorter duration of action than sulfonylureas. May prevent the rapid, transient rise in blood glucose that occurs immediately following a meal. | 60 or 120 mg three times daily | \( C_{\text{max}} = 3.09 \pm 1.64 \mu g/ml \) AUC = 6.93 ± 1.99 µg.h/ml [18] |
| Repaglinide (Prandin) | 2-ethoxy-4-[[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid C₂₇H₃₆N₂O₄ | Stimulates insulin production. Rapid onset and short duration of action. Immediately before a meal. | | \( C_{\text{max}} = 30.96 \pm 9.06 \mu g/l \) AUC = 36.03 ± 6.00 µg.h/l [19] |
| Rosiglitazone maleate (Avandia) | S-[[4-[[2-[[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione C₁₈H₁₉N₃O₃S | Attaches to insulin receptors on cells throughout the body increasing insulin sensitivity. | 4–8 mg daily | \( C_{\text{max}} = 724.3 \pm 135.7 \text{ ng/ml AUC} = 4024 \pm 956 \text{ ng.h/ml} \) [20] |
| Pioglitazones (Actos) | S-[[4-[[2-[[5-ethyl(pyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione C₁₈H₂₀N₂O₃S | Same as rosiglitazone. | 15–45 mg daily. | \( C_{\text{max}} = 932 \pm 335 \text{ ng/ml AUC} = 8.61 \pm 3.66 \text{ mg.h/l} \) [21] |
| Oral hypoglycemic drugs (Brand name) | Chemical name and formula | Chemical structure | Mechanism of primary action | Typical dosage/blood levels | $C_{\text{max}}$ & AUC of drug |
|-------------------------------------|--------------------------|-------------------|-----------------------------|-----------------------------|-----------------------------|
| Miglitol (Glycet)                   | 1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol $C_{8}H_{17}NO_{5}$ | ![Chemical structure](image) | Inhibitors of intestinal $\alpha$-glucosidase enzymes, resulting in delayed breakdown of carbohydrates and delayed glucose absorption, reducing postprandial hyperglycemia. | 25–100 mg three times before meals. | $C_{\text{max}} = 1883.9 \pm 912.4 \mu\text{g/l}$ AUC = $7592.7 \pm 4207.4 \mu\text{g.h/l}$ [22] |
| Acarbose (Precose)                  | (3R,4R,5S,6R)-5-[[2R,3R,4S,5S,6R]-3,4-dihydroxy-6-methyl-5-[[15,4R,5S,6S]-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl][oxy-6-(hydroxymethyl)]oxane-2,3,4-triol $C_{25}H_{43}NO_{18}$ | ![Chemical structure](image) | Slows down the actions of $\alpha$-amylase and $\alpha$-glucosidase enzymes. | 25–100 mg three times daily. | Data not available. |
| Sitagliptin                         | (3R)-3-amino-1-[[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one $C_{16}H_{15}F_{6}N_{5}O$ | ![Chemical structure](image) | Inhibits dipeptidylpeptidase-4, increases insulin secretion and lowers glucagon secretion. | 100 mg once daily. | $C_{\text{max}} = 706 \mu\text{M}$ AUC = 7.13$\mu\text{M.h}$ [23] |
| Chemical name and formula | Chemical structure | Mechanism of primary action | Typical dosage/blood levels | C_{\text{max}} \& \text{AUC of drug} |
|--------------------------|-------------------|----------------------------|-----------------------------|---------------------------------|
| Lovastatin (Mevacor, Lipivas, etc.) | ![Lovastatin structure](image) | Readily hydrolyzes in vivo to the corresponding \(\beta\)-hydroxyacid, a potent inhibitor of HMG-CoA reductase. Stimulates the production of low-density lipoprotein receptors in the liver. | 10–80 mg daily. C_{\text{max}} = 5.57 \pm 0.61 \text{ ng/ml} AUC = 39.45 \pm 3.23 \text{ ng.h/ml} \[25\] | |
| Pravastatin (Mevastatin, Selectin, Elisor, etc.) | ![Pravastatin structure](image) | Inhibits HMG-CoA reductase and hepatic synthesis of VLDL-C, reducing circulating cholesterol and LDL-C. | 40 mg daily. Maximum dose is 80 mg. C_{\text{max}} = 115.8 \pm 77.5 \text{ ng/ml} AUC = 259.0 \pm 133.4 \text{ ng.h/ml} \[26\] | |
| Simvastatin (Lipex, Cholestat, Zocor, etc.) | ![Simvastatin structure](image) | The six-membered lactone ring of simvastatin is hydrolyzed in vivo to generate mevinolinic acid, an active metabolite structurally similar to HMG-CoA. Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase. | 5–80 mg daily. C_{\text{max}} = 16.3 \pm 81.4 \text{ ng/ml} AUC = 93.5 \pm 70.1 \text{ ng.h/ml} \[27\] | |
| Atorvastatin (Lipitor, Tulip, Torvast, etc.) | ![Atorvastatin structure](image) | Selectively and competitively inhibits HMG-CoA reductase. | 20–40 mg daily. C_{\text{max}} = 44.7 \pm 61.3 \text{ ng/ml} AUC = 164.7 \pm 58.1 \text{ ng.h/ml} \[27\] | |
| Fluvastatin (Lescol, Cranoc, Canef, etc.) | ![Fluvastatin structure](image) | Selectively and competitively inhibits HMG-CoA reductase. | 20–80 mg daily. C_{\text{max}} = 60.81 \pm 38.26 \text{ ng/ml} AUC = 246.97 \pm 141.95 \text{ ng.h/ml} \[28\] | |
| Rosuvastatin (Crestor) | ![Rosuvastatin structure](image) | Competitive inhibitor of HMG-CoA reductase. | 10–40 mg daily. C_{\text{max}} = 12.3 \pm 7.0 \text{ ng/ml} AUC = 124 \pm 71 \text{ ng.h/ml} \[29\] | |
| Gemfibrozil (Lipozid, Lopid, Bolotol, Gemlipid, etc.) | ![Gemfibrozil structure](image) | Increases the activity of extrahepatic LPL, increasing lipoprotein triglyceride lipolysis. Inhibits synthesis and increases the clearance of apolipoprotein B. | 600 mg twice a day. Maximum daily dose 1200 mg. C_{\text{max}} = 18.57 \pm 6.61 \mu\text{g/ml} AUC = 75.19 \pm 26.30 \mu\text{g.h/ml} \[28\] | |
| Chemical name and formula | Chemical structure | Mechanism of primary action | Typical dosage/blood levels | Cmax & AUC of drug |
|--------------------------|-------------------|----------------------------|-----------------------------|---------------------|
| Colestipol (Cholestabyl, Colestid) | N‘-(2-aminoethyl)-N-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine; 2-(chloromethyl)oxirane | A non-absorbed, lipid-lowering polymer. Binds bile acids in the intestine, impeding their reabsorption. This upregulates cholesterol 7-(alpha)-hydroxylase, increasing the conversion of cholesterol to bile acids. | 2–16 grams (tablets) or 5–30 grams for the granules per day. | Data not available. |
| Fenofibrate (Antara, Lipidil, Procofen, etc.) | propan-2-yl 2-[4-(4-chlorobenzoyl)phenyl]-2-methylpropanoate | Activates Peroxisome proliferator-activated receptor alpha, increasing lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III. | 40–120 mg per day. | Cmax = 9.00 μg/ml AUC = 56.4 μg.h/ml [30] |
| Niacin (Diacin, Daskil, Nicoside, Simcor, etc.) | pyridine-3-carboxylic acid | Binds to nicotinate D-ribonucleotide pyrophosphate phosphoribosyltransferase, nicotinic acid phosphoribosyltransferase, nicotinate N-methyltransferase and the niacin receptor. Decreases esterification of hepatic Tg. | Recommended daily allowance range from 2 to 18 mg a daily. | Cmax = 4.61 ± 1.30 μg/ml AUC = 11.6 ± 1.24 μg.h/ml [31] |
| Anti-hypertensive drugs (Brand name) | | | | |
| Ramipril (Acovil, Vesdil, Delix, etc.) | (2S,3aS,6aS)-1-[(2S)-2-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[d]pyrrole-2-carboxylic acid | Competes with angiotensin I for binding at the angiotensin-converting enzyme (ACE), blocking the conversion of angiotensin I to angiotensin II. | 2.5–20 mg daily. | Cmax = 16.6 ± 13.4 ng/ml AUC = 39.5 ± 31.2 ng.h/ml [32] |
| Lisinopril (Zestril, Linopril, Lisipril, etc.) | (2S)-1-[(2S)-6-amino-2-[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid | Competes with angiotensin I for its binding site on ACE. | 10–40 mg daily. | Cmax = 79.8 ± 39.4 μg/ml AUC = 992.8 ± 520.5 μg.h/ml [33] |
| Amlodipine (Norvasc, Amvaz, Lotrel, Lipinox, etc.) | O3-ethyl O5-methyl 2-(2-aminoethoxyethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate | Inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes, causing dilation of coronary and systemic arteries. | 5–10 mg once daily. | Cmax = 19.8 ± 6.7 ng/ml AUC = 359.2 ± 129.5 ng.h/ml [34] |
| Chlorthalidone (Thalitone, Oradil, Zambesil, Hygroton, etc.) | 2-chloro-5-(1-hydroxy-3-oxo-2H-isodindol-1-yl)benzenesulfonamide | Indirectly increases potassium excretion via the sodium-potassium exchange mechanism by increasing the delivery of sodium to the distal renal tubule. | 25–100 mg once daily. | Cmax = 3.15 ± 0.52 μg/ml AUC = 5.55 ± 1.58 μg.h/ml [35] |
Reducing Antioxidant Power (FRAP) Assay, have shown that some drugs do show antioxidant properties (our unpublished data). While the FRAP assay was originally developed to investigate antioxidant power in biological samples, such as plasma and urine, it has since been applied to foods and health products, and since it is a test for the intrinsic chemical antioxidant properties of an agent, it was applied to drugs in this instance [42,43].

Studies by other investigators have shown that these drugs used in the management of DM can improve antioxidant status and ameliorate oxidative stress in cell culture, animal, and human trials (Table 4) [44,45].

The antioxidant effects of statins have come under intense research [90–92], Atorvastatin has decreased superoxide production in human endothelial cells exposed to high glucose, and also protected these cells from hydrogen peroxide mediated damage [93,94]. In human studies, statins have been shown to protect lymphocytic DNA from oxidative damage, decrease concentrations of oxidized-LDL, plasma concentrations of protein-bound tyrosines, urinary F2-...
bovine aortic endothelial cells, though the results in these studies are mixed [98,99]. Metformin significantly decreased urinary F₂-isoprostanes and increased plasma concentrations of vitamins A and E in Type 2 DM subjects, although no effects were seen in serum malondialdehyde (MDA) and total antioxidant status (TAS) in subjects with polycystic ovarian syndrome after 12-week treatment [49,51]. In the same study, treatment with rosiglitazone was able to increase plasma TAS from 0.95 to 1.21 mmol/l significantly ($p < 0.005$), and decrease plasma MDA from 7.46 to 4.02 mmol/l ($p < 0.001$). In an animal study of Type 2 DM mice, rosiglitazone treatment for 7 days was able to significantly decrease serum F₂-isoprostanes and vascular superoxide production, and increase vascular catalase concentrations (all $p < 0.05$) [100].

### Table 3. FRAP value of some drugs used in the management of Type 2 DM.

| Drug                        | FRAP per tablet/capsule (μmol) |
|-----------------------------|---------------------------------|
| **Hypoglycemic agent**      |                                 |
| Metformin HCl (Brand A), 500 mg | 165.6 – – – – – –                |
| Metformin HCl (Brand B), 500 mg | 165.6 – – – – – –                |
| Chlorpropamide, 250 mg      | 276.7 – – – – – –                |
| Glipizide, 80 mg            | 323.4 – – – – – –                |
| Glipizide, 5 mg             | 445.5 – – – – – –                |
| Tolbutamide, 500 mg         | 270.4 – – – – – –                |
| Pioglitazone, 2 mg          | 356.4 – – – – – –                |
| Rosiglitazone, 2 mg         | 357.4 – – – – – –                |
| Glibenclamide, 5 mg         | 494 – – – – – – –                |
| **Lipid-lowering agent**    |                                 |
| Fluvastatin sodium, 40 mg   | 433.5 – – – – – –                |
| Simvastatin, 10 mg          | 418.6 23 26 14                   |
| Pravastatin sodium, 10 mg   | 424.5 – – – – – –                |
| Lovastatin, 20 mg           | 404.5 – – – – – –                |
| Acipimox, 250 mg            | 154.1 – – – – – –                |
| Bezafibrate, 400 mg         | 361.8 – – – – – –                |
| Gemfibrozil, 900 mg         | 250.3 – – – – – –                |
| Fenofibrate, 300 mg         | 260.8 – – – – – –                |
| Probucol, 250 mg            | 519.6 – – – – – –                |
| Rosuvastatin, 10 mg         | 481.5 – – – – – –                |
| Nicotinic acid, 500 mg      | 123.1 – – – – – –                |
| Atorvastatin calcium, 10 mg | 1209.4 – – – – – –               |
| **Antihypertensive agent**  |                                 |
| Metoprolol, 50 mg           | 267.4 – – – – – –                |
| Doxazosin mesylate, 5 mg    | 451.5 – – – – – –                |
| T ritace, 5 mg              | 416.5 – – – – – –                |
| Valsartan, 80 mg            | 435.5 – – – – – –                |
| Amlodipine, 5 mg            | 408.9 – – – – – –                |

FRAP: ferric reducing antioxidant power; HCl: hydrochloric acid; NaOH: sodium hydroxide; ––: no detectable FRAP.

iso prostano ses as well as to increase concentrations of an erythrocyte antioxidant enzyme, superoxide dismutase (SOD) [59,62,66,69,81,87,93,95].

Although both in vitro and in vivo studies provide evidence of the antioxidant properties of statins, conflict exists with regard to the effect of statins on plasma tocopherols (vitamin E). Cangemi et al. [69] found in a retrospective study that subjects with metabolic syndrome on statin therapy (simvastatin or atorvastatin) for 6 months or more had significantly higher concentrations of plasma vitamin E ($p = 0.02$) and lower concentrations of plasma 8-hydroxy-2'-deoxyguanosine (8-OHdG) ($p < 0.01$) compared to those subjects with metabolic syndrome not treated with statins [81]. The statin-treated group had similar plasma vitamin E and 8-OHdG concentrations as the healthy control group. While in Jula et al.’s (2002) study of hyper-cholesterolemic subjects, 12-week treatment with simvastatin had no effect on serum ascorbic acid, but decreased serum α-tocopheryl by 16.2% and β-carotene by 19.5% [60]. Plasma α-tocopherol was also decreased in normocholesterolemic subjects given atorvastatin for 3 months [60,65]. It is noted here though that Jula’s and Oranje’s work did not lipid-standardize the measurements of the lipid-soluble vitamins, and therefore, the decreases seen may simply be due to the lipid-lowering effect of the statins [60,65]. Plasma α-tocopherol was not significantly changed after 2 months of simvastatin treatment in hyper-cholesterolemic subjects in De Caterina’s [59] study, and additional supplementation with vitamin E did not enhance the antioxidant effect seen when simvastatin was taken alone. The biguanide metformin is one of the most widely prescribed oral hypoglycemic medications [96,97]. In vivo studies have shown that metformin was able to scavenge hydroxyl radicals, and to reduce the production of ROS in Type 2 DM, antioxidant status, oxidative stress, and results of antioxidant supplementation trials

There are many reports of decreased antioxidant status in Type 2 DM patients [101–107]. Studies, summarized in Table 5, show also that Type 2 DM is a condition of increased oxidative stress [44,45,103,107–109].

What is the source of increased oxidative stress in DM?

There is no generally agreed source of the increased oxidative stress found in DM [120]. It has been proposed, but disputed, that acute elevation of plasma glucose is the trigger [120–122]. Others suggest that it is glycemic variability that is the root cause [123,124]. However, conceptually at least, if antioxidant status is high, then oxidative damage to key biomolecules in Type 2 DM might be avoided, improving outcome regardless of the exact relationship between glycemic control and generation of reactive oxygen species. This has led to the suggestion that antioxidant supplementation should be investigated as an adjunct therapy in DM, the hypothesis being that increasing antioxidant defense will lower oxidative stress and help slow or prevent vascular changes that lead to complications [125,126].

Can antioxidant supplementation decrease oxidative stress in DM?

This has been explored in human supplementation trials with various types and combinations of antioxidants, and using diverse biomarkers of oxidative stress. Some researchers have also investigated the effects of antioxidant supplementation on inflammation, lipids, blood pressure, and glycemic control. These studies (summarized in Table 5) have not revealed clear evidence of benefit. However, none of these studies considered the possible confounding effect of therapy with drugs with antioxidant (or other) effects.

Evidence of decreased oxidative stress in DM after antioxidant supplementation

In Ward et al.’s [127] study, the only oxidative stress biomarker measured was plasma and 24-hour urine F₂-isoprostanes. It was found that plasma F₂-isoprostanes were significantly reduced in both the tocopherol treatment groups when compared to the placebo group, but no difference was seen in...
| Subject characteristics | Study description/duration of treatment | Outcome/biomarkers investigated | Results/comments |
|--------------------------|----------------------------------------|-------------------------------|------------------|
| **Type 2 DM patients [46]** | Glipizide alone (15 mg/day) [n = 74] with Aralia root bark extract (2.7 g/day) [n = 74] 8 weeks | HbA1c, fasting plasma glucose, 2h-postprandial plasma glucose, TC, and LDL-C | Both treatments decreased HbA1c (from 7.3 to 6.4% in combination group and from 6.9% to 6.5% in glipizide alone), compared to baseline (p < 0.05). |
| **Type 2 DM patients [47]** | Glibenclamide (5 mg/day) [n = 15] | Plasma lipid peroxides and plasma TRAP | Gliclazide significantly lowered plasma lipid peroxides (from 18.2 ± 3.9 to 13.3 ± 3.8 µmol/l), increased plasma TRAP (from 997.8 ± 132.5 to 1155.6 ± 143 µmol/l), compared to baseline control (p = 0.0001). |
| **Type 2 DM patients Healthy, age, and gender-matched controls [46]** | Gliclazide (80 mg/day) [n = 15] | | |
| | Glibenclamide 10–15 mg/day [n = 30] | | |
| | Metformin 1500 mg/day [n = 29] | | |
| **Type 2 DM patients Healthy, age, and gender-matched controls [46]** | Glipizide 80–240 mg/day [n = 33] | TAS and plasma levels of o-Lab | In group 1, both the o-Lab level (236.6nl/ml/l) and TAS (1.39 mmol/l) were similar to those of control group, o-Lab level (435.7nl/ml/l, p < 0.05) was highest and TAS (0.85 mmol/l, p < 0.05) was lowest in group 3, compared with control. |
| **Newly diagnosed Type 2 DM subjects [49]** | Metformin or glipizide uptitrated until good glycemic control was achieved, (up to 2550 mg/day for metformin and of 240 mg/day for glipizide) [n = 26] 12 weeks | Urinary 8-iso-PGF2α, plasma vitamins A and E | Metformin significantly decreased 8-iso-PGF2α (from 708 to 589 pg/mg creatinine, p < 0.001), while no changes in these parameters were observed with glipizide treatment. Glipizide treatment did not affect plasma concentrations of vitamin A and E. Metformin increased plasma vitamin A from 1.84 to 2.23 µmol/l and vitamin E from 12.8 to 18.2 µmol/l, (no p value given and unsure if vitamin E value was lipid-standardized). |
| **Type 2 DM patients, non-smokers, non-drinkers, free of chronic disease [50]** | Gliclazide [n = 16] | Erythrocyte GPx, GST, catalase, MDA, and GSH | |
| | Metformin [n = 15] | | |
| | Diet treatment [n = 15] | | |
| | Time frame and dose unknown | | |
| **Lean polycystic ovary syndrome (BMI <25 kg/m²) subjects and age-weight-matched healthy controls DM, hypertension and renal dysfunction were exclusion criteria [51]** | Rosiglitazone (4 mg/day) [n = 25] | Serum MDA and TAS | TAS increased (from 0.95 to 1.21 mmol/l, p < 0.005) and MDA decreased (from 7.46 to 4.02 nmol/ml, p < 0.001) after rosiglitazone, but no changes were seen in these parameters after metformin. After treatment, MDA concentrations significantly higher in the metformin group compared with the rosiglitazone group (p < 0.05). No significant difference in antioxidant enzyme activities and levels of MDA between the drug treatment groups. No differences were seen in MDA between the three groups. |
| **Healthy subjects aged 31–65 years with BMI > 27 kg/m² Randomized, double-blind study [52]** | Rosiglitazone (4 mg/day) [n = 20] Placebo [n = 20] 6 months | Plasma peroxides | Compared with placebo, plasma peroxides decreased significantly after 6 months of rosiglitazone treatment (~15%). |
| **Type 2 DM patients on a stable dose of oral hypoglycemic drugs for at least 6 months prior to the study, with HbA1c 7–10% and with postprandial plasma glucose > 8 mmol/l [53]** | Repaglinide and diet treatment [n = 21] Repaglinide and metformin [n = 25] | TAS, SOD, Hba1c | TAS increased from 20.62 ± 0.9 to 24.31 ± 1.4 µgH2O2/ml/min (p < 0.05) in repaglinide-treated group; and also serum SOD activity increased from 208.1 ± 10.7 to 237.9 ± 10.6 U/l (p < 0.0004). Both showed a significant difference compared to control group. Hba1c level was decreased in repaglinide-treated group from 8.6 ± 0.97 to 8.0 ± 1.0% compared to control group (8.3 ± 1.4–8.2 ± 1.2%, p = 0.01). |

(Continued)
| Subject characteristics | Study description/duration of treatment | Outcome/biomarkers investigated | Results/comments |
|--------------------------|----------------------------------------|---------------------------------|-----------------|
| Newly diagnosed Type 2 DM patients [54] | Pioglitazone (30 mg/day) [n = 30] Metformin (1000 mg/day) [n = 50] No medication (lifestyle modification) for 3 months [n = 49] | AOPP, AGE, FRAP, enzymatic activities of PON, LCAT, LPL | Significant decreases in AOPP (from 154.20 ± 3.75 to 125.45 ± 3.20 μmol/l, p < 0.001) and AGE (from 68.62 ± 0.52 to 59.58 ± 0.91%, p < 0.001) observed in patients taking pioglitazone, whereas FRAP (from 1051.30 ± 25.54 to 1183.27 ± 46.67 μmol/l, p = 0.003) and activities of both PON (from 37.07 ± 2.19 to 48.25 ± 3.00 U/l, p < 0.001) and LPL (from 2.27 ± 0.17 to 5.03 ± 0.19 U/ml, p < 0.001) increased significantly. No changes were seen in control group, except a decrease in FRAP. |
| 15 Type 2 DM patients and 20 healthy, age-, and sex-matched controls [53] | Metformin (1700 mg/day) [n = 15] Placebo [n = 20] 3 months | MDA, SOD, ascorbic acid, α-tocopherol, AOPP, AGE, NAG. Increases in serum NAG activity (p < 0.05) and plasma MDA were found 1 month after metformin treatment, whereas plasma MDA (p < 0.01), ascorbic acid (p < 0.01), and the α-tocopherol/(cholesterol + triglyceride) ratio (p < 0.001) increased significantly after metformin treatment. | |
| Type 2 DM patients [56] | Metformin (850–2000 mg/day) [n = 110] Placebo [n = 98] 24 weeks | HbA1c, intracellular ROS generation, AOPP, AGE. Compared to baseline, HbA1c, AOPP, and AGE decreased significantly from 8.7 ± 1.4 to 6.9 ± 0.75% (p < 0.05), from 179.64 ± 13.6 to 120.65 ± 10.5 μmol/l (p < 0.001), and from 107 ± 10.4 to 78 ± 7.0 pmol/l (p < 0.05), respectively. Reduction in ROS generation was seen in white blood cells in patients in metformin group. | |
| 87 Type 2 DM patients and 45 healthy controls [57] | Dietary treatment only (newly diagnosed DM patients) [n = 42] | Serum LDL-C oxidation, HbA1c | Compared to baseline, a significant reduction in AOPP (from 8.37 ± 0.36 to 7.36 ± 0.59 μmol/l, p < 0.001) and from 0.082 to 0.06 (p < 0.001), respectively, after metformin. |
| Newly diagnosed Type 2 DM patients [58] | Metformin (1000 mg/day) [n = 50] No medication (lifestyle modification) [n = 49] 3 months | AOPP, AGE, FRAP, PON, LCAT, LPL. Compared to baseline, a significant reduction in AOPP (from 137.52 ± 25.59 to 118.45 ± 38.42 μmol/l, p < 0.001), and AGE (from 69.28 ± 4.58, 64.31 ± 8.64% (p = 0.012) seen after metformin. FRAP (from 1060.67 ± 226.69 to 1347.80 ± 251.40 μmol/l, p < 0.001) and PON (from 29.85 ± 23.18 to 37.86 ± 27.60 U/l, p = 0.012) increased significantly. Significant differences between metformin and lifestyle modification were observed only in AOPP (p = 0.007), FRAP, and AGE (p < 0.001). | |

| Subject characteristics | Study description | Outcome/biomarkers investigated | Results/comments |
|--------------------------|------------------|---------------------------------|-----------------|
| Simvastatin | Cross-over trial with two groups Group 1: simvastatin 10–40 mg/day, titrated to achieve ≥20% reduction in cholesterol after 60 days Group 2: same simvastatin treatment + vitamin E 600 mg/day with meals [n = 43] 2 months | Plasma vitamin E, 8-hour urinary 8-iso-PGF2α and oxLDL | Urinary 8-iso-PGF2α and ox-LDL was significantly decreased by simvastatin alone (both p < 0.05), but the addition of vitamin E produced no further reduction in urinary 8-iso-PGF2α or ox-LDL. Inverse correlation between 8-iso-PGF2α and vitamin E was seen (r² = 0.024, p = 0.318). |
| Hypercholesterolemic subjects (with serum cholesterol > 200 mg/dl and proven vascular disease: coronary, carotid, peripheral arterial disease) [59] | Subjects randomly allocated to habitual diet [n = 60] or dietary treatment group [n = 60]. Each group further randomized to receive simvastatin (20 mg/day) or placebo 12 weeks | Serum α-tocopherol, β-carotene, and ascorbic acid. Serum LDL-C fraction used for the determination of diene conjugation and total peroxyl radical trapping antioxidant potential. Antioxidant potential of isolated LDL-C samples was determined. | Simvastatin treatment did not affect serum ascorbic acid, but decreased serum α-tocopherol by 16.2% and β-carotene by 19.5% and total peroxyl radical trapping potential of serum LDL-C by 16.9%. Relative antioxidant power of LDL-C preparations (LDL-C TRAP/mmol of LDL-C) increased by 17.4 Note: The crude value of α-tocopherol was not corrected for the cholesterol levels. |
| Simvastatin | Subjects randomly allocated to habitual diet [n = 60] or dietary treatment group [n = 60]. Each group further randomized to receive simvastatin (20 mg/day) or placebo 12 weeks | Serum α-tocopherol, β-carotene, and ascorbic acid. Serum LDL-C fraction used for the determination of diene conjugation and total peroxyl radical trapping antioxidant potential. Antioxidant potential of isolated LDL-C samples was determined. | Simvastatin treatment did not affect serum ascorbic acid, but decreased serum α-tocopherol by 16.2% and β-carotene by 19.5% and total peroxyl radical trapping potential of serum LDL-C by 16.9%. Relative antioxidant power of LDL-C preparations (LDL-C TRAP/mmol of LDL-C) increased by 17.4 Note: The crude value of α-tocopherol was not corrected for the cholesterol levels. |
### Hypercholesterolemic patients [61]

Three-phase protocol (1) Washout, without statin treatment (basal) for 1 month (2) Simvastatin (20 mg/day) for 2 months (3) Simvastatin (20 mg/day) + α-tocopherol (400 UI/day) for 2 months \(n = 25\)

- Plasma α-tocopherol, lycopene, retinol, β-carotene, nitrotyrosine, and GSH

The concentration of retinol increased by 37% in group 2. No difference seen for other lipid-soluble antioxidants in groups 2 and 3. Simvastatin alone and simvastatin taken with α-tocopherol decreased plasma nitrotyrosine to the same degree \(p < 0.05\) compared to control group. GSH concentrations were not affected by any treatment.

### Simvastatin

**Patients with LDL > 130 mg/dl [62]**

Simvastatin (20 or 40 mg/day) \(n = 72\) 8 weeks

- Oxidative DNA damage in lymphocytes

Simvastatin treatment decreased DNA damage, reduction of 10.5–8.8% in tail DNA, 55.5–44.5 \(µm\) in tail length, and 7.5–5.2 in tail moment (tail DNA: \(r = 0.58\); tail length: \(r = 0.58\); tail moment: \(r = 0.57\) respectively, \(p < 0.001\) for all when compared to baseline.

### Subjects with LDL-C ≥ 130 mg/dl

Subjects free of hepato- and renal disorders, DM, history of CVD and had not taken any cholesterol-lowering agent during the preceding 6 months [63]

Simvastatin (20–40 mg/day) administered Randomly assigned to 20 mg/day \(n = 39\) or 40 mg/day \(n = 37\) 8 weeks

- Ox-LDL, TRAP, and plasma antioxidant vitamins (retinol, α-tocopherol, γ-tocopherol, coenzyme Q10 and carotenoids)

In all subjects, simvastatin treatment improved plasma antioxidant status as assessed by TRAP (increased from 1.20 to 1.23 µM, \(p < 0.05\)). Ox-LDL was significantly decreased from 63.4 to 41.5 U/l \(p < 0.0001\). Significant increases in the levels of retinol \(p < 0.001\), α-tocopherol \(p < 0.001\) and γ-tocopherol \(p < 0.005\) seen. Coenzyme Q10 and carotenoids remained unchanged.

### Simvastatin

**Type 2 DM patients with dyslipidemia, Type 2 DM patients without dyslipidemia and healthy control subjects [64]**

Observational study Dyslipidemic Type 2 DM patients on 20 mg simvastatin daily for an average of 2 years, \(n = 9\)

- Oxidative DNA damage in leukocytes; plasma MDA; TAR; HbA1c; PON activity; CRP

TAR and PON activity was significantly increased in patients under simvastatin treatment when compared to those without simvastatin treatment, whereas MDA, CRP, and DNA damages were found decreased significantly compared to patients without simvastatin treatment and patients without dyslipidemia.

### Atorvastatin

**Normocholesterolemic Type 2 DM patients All subjects were (treated with oral glucose-lowering agents and/or insulin) [65]**

Atorvastatin (10 mg/day) \(n = 10\) Placebo \(n = 9\) 3 months

- LDL oxidizability (dienes production), plasma α-tocopherol

Dienes production lower in the atorvastatin group (487 vs. 538 nmol, \(p = 0.012\)) compared to placebo. Plasma α-tocopherol was decreased in the atorvastatin group (8.67 vs. 10.55 µg/ml plasma, \(p = 0.036\)) compared to the placebo group.

### Atorvastatin

**Subjects without clinical evidence of carotid artery disease, active liver disease and renal insufficiency and with LDL-C ≥ 130 mg/dl [66]**

Atorvastatin (10 mg/day) \(n = 35\) 12 weeks

- Plasma levels of protein-bound chlorotyrosine, nitrotyrosine, dityrosine, and orthotyrosine, plasma CRP.

Decrease in chlorotyrosine, dityrosine, and nitrotyrosine of 30, 32, and 25%, respectively, \(p < 0.02\) each) after atorvastatin. Non-significant decreases in CRP and orthotyrosine seen (11 and 9%, respectively, \(p > 0.01\) each).

### Hyperlipidemic Type 2 DM patients with LDL-C >130 mg/dl [67]

Atorvastatin (10 mg/day), \(n = 110\) 24 weeks

- Percentage change in free radical scavenger enzymes, SOD, GSH, GST, GPx, plasma MDA.

Compared to baseline, SOD, and GSH activities increased significantly \(p < 0.001\), whereas plasma MDA level significantly decreased \(p < 0.001\). No changes were seen in other biomarkers.

Serum IL-6 (from 2.27 ± 0.55 to 1.36 ± 0.19 pg/ml), TNF-α (from 2.51 ± 0.54 to 1.62 ± 0.18 pg/ml), sVCAM-1 (from 484.7 ± 31.2 to 363.5 ± 13.2 ng/ml), CRP (from 3.84 ± 1.16 to 2.34 ± 0.71 mg/l) and ADMA (from 1.21 ± 0.18 to 0.72 ± 0.08 µmol/l) showed significant decreases after atorvastatin treatment \(p < 0.05\) compared to baseline, while no changes were seen in the other two groups.

### Type 2 DM patients without macroangiopathy [68]

Atorvastatin (10 mg/day), \(n = 15\) Vitamin C (2 g/day), \(n = 13\) No treatment control, \(n = 14\) 4 weeks

- Serum IL-6, TNF-α, sVCAM-1, CRP, and ADMA.

(Continued)
| Subject characteristics                                      | Study description/duration of treatment                                                                 | Outcome/biomarkers investigated                                      | Results/comments                                                                                                                                 |
|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypercholesterolemic patients (not taking statins or antioxidants) free of cardiovascular disease, liver disease, and renal insufficiency. Healthy controls [69] | Subjects were randomized to A) diet only [n = 15] B) diet + atorvastatin (10 mg/day) [n = 15] C) healthy control subjects [n = 20] Followed-up for 30 days after treatment | Urinary 8-iso-PGF2α and plasma vitamin E and concentrations | A reduction of 8-iso-PGF2α (~37.1%, p < 0.01) and ox-LDL (~58.9%, p < 0.01), increase of vitamin E (42%, p < 0.01) and a reduction of cholesterol (~24.9%, p < 0.01) seen after 30 days. In vitro study showed that atorvastatin dose-dependently inhibited LDL-C oxidation and 8-iso-PGF2α formation. |
| Type 2 DM patients [70]                                      | Atorvastatin (10 mg/day) [n = 23] Curcumin (120 mg twice/day) [n = 23] Placebo [n = 21] 8 weeks       | Plasma MDA                                                            |                                                                                                                                             |
| Fenofibrate                                                  | Fenoibrate (200 mg/day) only, [n = 18] Coenzyme Q10 (200 mg/day) only, [n = 19] Fenoibrate (200 mg/day) and coenzyme Q10 (200 mg/day), [n = 19] Placebo, [n = 18] 12 weeks | HbA1c and plasma F2 isoprostanes                                     | Fenoibrate did not result in significant changes in any markers.                                                                                     |
| Fenoibrate                                                  | Fenoibrate (300 mg/day) [n = 20] 8 weeks to 3 months                                                    | Plasma MDA, TAS, GPx, conjugated diene formation                       | Fenoibrate treatment resulted in significant reduction conjugated diene from 33.7 to 19.7 µmol/l (~42%) (p < 0.0001). A tendency toward lower TAS (from 1.72 to 1.62 µmol/l, p = 0.061) and a similarly non-significant trend to decreased MDA production (from 1.95 to 1.81 µmol/l, p = 0.199) were noted. Significant increase in GPx activity (80%, from 5.8 at the baseline to 10.45 U/ml) was seen. |
| Lovastatin                                                  | Policosanol (10 mg/day); [n = 16] Lovastatin (20 mg/day); [n = 16] 8 weeks treatment after 4 weeks on a cholesterol-lowering diet | Plasma TBARS                                                          | Lovastatin decreased plasma TBARS by 11.5% compared to baseline (p < 0.001).                                                                                     |
| Lovastatin                                                  | Lovastatin (20 mg/day), [n = 30] Hypolipemic diet [n = 28] Control group [n = 13] 6 months treatment   | Serum TAS and 8-OHdG                                                  | A significant decrease in 8-OHdG from 15.6 to 12.5 ng/ml (p = 0.04), and a significant increase in the TAS level from 1.28 to 1.37 mmol/l (p = 0.011) was seen in lovastatin-treated group. TAS decreased in the hypolipemic diet-treated group from 1.55 to 1.45 mmol/l (p = 0.007). |
| Fluvastatin                                                  | Fluvastatin (20 mg/day), [n = 6] Controls, [n = 6] 12 weeks.                                          | Plasma LDL size, LHPO, TBARS, oxysterols                              | LHPO (from 43.3 ± 13.1 to 14.4 ± 5.1 nmol/mgLDL), TBARS (from 8.83 ± 11.1 to 4.27 ± 0.65 nmol/ml), Total oxysterols (from 61.25 ± 8.32 to 38.95 ± 6.57 ng/ml) decreased significantly after 12 weeks in treatment group compared to baseline (p < 0.05). |
| Gemfibrozil                                                  | Gemfibrozil (1200 mg/day) [n = 56] 3 months                                                           | Serum PON activity                                                   | Serum PON activity increased from 100.2 to 118.7 U/l, p < 0.001.                                                                                     |
| Combination                                                  | Cross-over study [n = 45] Simvastatin alone (20 mg/day) Ramipril (5–10 mg/day) and simvastatin Ramipril alone Each treatment for 2 months with a washout period of 2 months | Plasma MDA                                                           | Plasma MDA levels were decreased by 4 ± 7% (p = 0.026) and by 25 ± 4% (p < 0.001) in simvastatin alone or simvastatin with ramipril, respectively, when compared to baseline. |
Type 2 DM patients with dyslipidemia [78]

Cross-over trial Simvastatin (20 mg/day), \([n = 10]\); Fenofibrate (200 mg/day), \([n = 10]\) Treatment for 3 months; 2 month wash-out period, patients crossed over on other treatment for 3 months Healthy controls \([n = 24]\)

HbA1c, uric acid, homocysteine, plasma MDA, SOD, GSH, serum ascorbic acid, serum \(\alpha\)-tocopherol, NAG activity

Uric acid decreased from 370 ± 90 to 313 ± 107 µmol/l \((p < 0.01)\), MDA decreased from 2.78 ± 0.40 to 2.36 ± 0.36 µmol/l, and homocysteine increased from 11.9 ± 2.8 to 16.0 ± 4.5 µmol/l \((p < 0.001)\), in patients treated with fenofibrate, this was not found in those taking simvastatin.

Type 2 DM patients [79]

Rosiglitazone (4 mg/day) in addition to patients' current therapy for 12 weeks, followed by the addition of fenofibrate (200 mg/day) for another 12 weeks, \([n = 40]\) 24 weeks

HbA1c, Uric acid

Uric acid decreased significantly from 4.78 ± 1.1 to 4.41 ± 1.1 mg/dl \((p = 0.001)\), whereas HbA1c decreased from 9.95 ± 9.7 to 8.85 ± 8.5% compared to baseline. Addition of fenofibrate resulted in a significantly lower uric acid concentration when compared to rosiglitazone alone \((4.41 ± 1.1 \text{mg/dl vs. } 3.86 ± 0.99 \text{mg/dl, } p = 0.001)\)

Plasma \(\alpha\)-tocopherol levels were equally decreased by pravastatin and simvastatin \(-17.5 \mu\text{g/ml, } p = 0.002\) and \(-12.2 \mu\text{g/ml, } p = 0.006\) when compared to baseline. Pravastatin did not significantly affect plasma \(\gamma\)-tocopherol levels, simvastatin produced a significant increase \((22 \mu\text{g/ml, } p = 0.009)\)

Combination

Type 2 DM patients [79]

Rosiglitazone (4 mg/day) in addition to patients' current therapy for 12 weeks, followed by the addition of fenofibrate (200 mg/day) for another 12 weeks, \([n = 40]\) 24 weeks

HbA1c, Uric acid

Plasma \(\alpha\)- and \(\gamma\)-tocopherol

Plasma \(\alpha\)-tocopherol levels were equally decreased by pravastatin and simvastatin \(-17.5 \mu\text{g/ml, } p = 0.002\) and \(-12.2 \mu\text{g/ml, } p = 0.006\) when compared to baseline. Pravastatin did not significantly affect plasma \(\gamma\)-tocopherol levels, simvastatin produced a significant increase \((22 \mu\text{g/ml, } p = 0.009)\)

Subjects with metabolic syndrome, healthy control subjects [81]

Simvastatin \([n = 16]\) Atorvastatin \([n = 14]\) Metabolic syndrome patients not on statin \([n = 82]\) Healthy control subjects \([n = 80]\) Dosage not specified. >6-month statin treatment

Retrospective analysis of oxidative stress assessed by serum levels of 8-OHdG and vitamin E.

Statin-treated subjects had higher levels of vitamin E \((5.24 \text{vs. } 4.61 \text{µmol/mmol cholesterol, } p = 0.02)\) and decreased levels of 8-OHdG \((-27.0\% \text{vs. } -38.4\%, p = 0.001)\) compared with subjects not on statin. Statin treated subjects had similar vitamin E and 8-OHdG levels as control subjects.

Type 2 DM subjects with marked hypertriglyceridemia. All diabetic patients were treated with either metformin or a combination of metformin and a sulfonylurea to achieve HbA1c of < 9% before the study. 6-week washout/run-in period for lipid-lowering medications before subjects were randomly assigned to a treatment group [82]

(1) Atorvastatin 20 mg/day, \([n = 19]\); (2) Micronized fenofibrate 200 mg/day, \([n = 19]\) 6 weeks treatment period

Plasma oxLDL, 8-iso-PGF2α, ApoB and ApoA-I, E-selectin

Atorvastatin treatment significantly reduced plasma ApoB \((-43.2\%, p < 0.0001)\), as did treatment with fenofibrate \((-9.9\%, p = 0.01)\). OxLDL was significantly reduced in atorvastatin group \((-38.4\%, p < 0.0001)\). A tendency toward decreased 8-iso-PGF2α levels in atorvastatin group \((-52.1\%, p = 0.06)\) and decreased levels of oxLDL in fenofibrate group \((-8.8\%, p = 0.09)\) were observed. Under fenofibrate treatment, the % change in plasma levels of oxLDL was significantly and directly correlated with LDL-C \((r = 0.60, p = 0.06)\) and with the % change in soluble E-selectin levels \((r = 0.64, p = 0.003)\). Such associations were not significant in atorvastatin group.

Atorvastatin, 20 mg/day, \([n = 31]\); Rosuvastatin, 10 mg/day, \([n = 31]\) 3 months

TAC, TOS, LOOH

TAC increased significantly \((0.87 ± 0.17 \text{ to } 0.97 ± 0.13 \text{ mmol Trolox equiv/l, } p = 0.007)\) in atorvastatin group. No changes seen in other markers or in patients taking rosuvastatin.

(Continued)
### Table 4. Continued.

| Subject characteristics | Study description/duration of treatment | Outcome/biomarkers investigated | Results/comments |
|-------------------------|----------------------------------------|---------------------------------|------------------|
| **Valsartan**           | Hypertensive patients (BP > 140/90 mmHg) with mild diabetes or impaired glucose tolerance (HbA1c < 9%, requiring treatment by diet alone or an oral hypoglycemic) [84] | Valsartan (40–80 mg/day) – initial dose 40 mg/day, increased to 80 mg/day if the BP was still 140/90 mmHg after 1 month [n = 26] | Urinary 8-OHdG decreased significantly from 12.12 to 8.07 ng/mg. creatinine (p = 0.001). The decrease in 8-OHdG following valsartan treatment is independent of the amelioration in %HbA1c (or glucose metabolism). In contrast, concentrations of 8-isoprostanes did not alter significantly after 3 months of treatment (283.5 vs. 302.0 pg/mg. creatinine post-treatment, p = 0.559). |
| **Losartan**            | Type 2 DM patients with nephropathy [36] | Losartan (100 mg/day) [n = 678]; Matching placebo [n = 664] Mean follow-up duration of 3.4 years | Losartan reduced serum uric acid compared to placebo (p < 0.001). HbA1c level was not affected by losartan treatment. |
| **Niacin**              | Type 2 DM patients with reduced HDL cholesterol levels and metabolic syndrome [85] | Extended-release niacin from 500 mg/day for 3 months, with escalation to 1000 mg/day every month; [n = 15] Healthy controls [n = 10] | Decreased endothelial superoxide production (p = 0.004), NADPH oxidase activity (p = 0.04), myeloperoxidase activity (p = 0.02) and myeloperoxidase content (p = 0.01) were observed in subjects taking niacin, compared to placebo. Reduced lipid peroxidation of HDL seen in subjects taking niacin only when evaluated using electrophoresis mobility (p = 0.02) but not by measuring MDA concentration (p = 0.41), compared to placebo group. |
| **Others**              | Type 2 DM patients with hypertension, BP > 160/95 mmHg [37] | Captopril, [n = 16] Enalapril, [n = 16] Doses given according to patient requirement 12 weeks. | Both captopril and enalapril treatments gave rise to significant decreases in TBARS levels from 2.35 to 1.46 nmol MDA (p < 0.05) and from 2.44 to 1.72 nmol MDA (p < 0.01), respectively. |
|                         | Non-obese, normotensive patients with Type 2 DM [86] | Cross-over study Enalapril, 10 mg/day or 30 mg/day continuous-release Nifedipine, for 4 weeks, followed by 2-week washout period then crossed over to the other treatment for 4 weeks [n = 24] | Enalapril reduced LDL oxidation significantly (p = 0.001), whereas nifedipine increased LDL oxidation (p < 0.05). HbA1c level was not affected by either treatment. |
| **Others**              | Hypertensive patients Healthy control subjects [87] | (1) α-blocker: doxazosin (4 mg/day), [n = 20]; (2) β-blocker: metoprolol (100 mg/day), [n = 22]; (3) ACE inhibitor: ramipril (5 mg/day), [n = 20]; (4) angiotensin II antagonist: valsartan (80 mg/day), [n = 20]; (5) calcium channel blocker: amlodipine (10 mg/day), [n = 20]; Healthy controls [n = 51] 3 months | Erythrocyte MDA and SOD |
|                         | Type 2 DM patients with hypertension [88] | Carvedilol (initiated at 6.25 mg twice daily up to a maximum of 25 mg twice/day), [n = 16]; Metoprolol (initiated at 50 mg twice/day up to a maximum of 200 mg twice/day), [n = 18] In addition to patients’ current anti-hypertensive medications 5 months. | Erythrocyte MDA decreased (p < 0.001) and SOD increased (p < 0.05) in groups 3 and 4 when compared to baseline. No obvious effect on oxidative stress was noted in other groups. |
|                         | Healthy control subjects | | No significant differences were observed between either groups and compared to baseline. |
Subjects were randomly assigned to (1) Candesartan 8 mg/day, 
\[ n = 22 \] or valsartan 80 mg/day, 
\[ n = 22 \] (2) Trichlormethiazide 2 mg/day 
\[ n = 33 \] 8 weeks treatment with either candesartan or valsartan for 8 weeks reduced the levels of urinary 8-epi-PGF2\(\alpha\) and 8-OHdG, whereas levels were not altered with trichlormethiazidetreatment. Significant correlation was observed between the reduction of the urinary 8-epi-PGF2\(\alpha\) and 8-OHdG and the studied biomarkers between the candesartan and the valsartan group.

In another study, vitamin C supplementation had no effect on the vitamin E concentration of HDL-C in patients with diabetes, although an increase in intracellular glutathione (GSH) was seen \( (p < 0.01) \) when compared to the placebo group [129]. The investigators state that these subjects were on either glibenclamide, metformin, or insulin to control their diabetes, but it is likely that the subjects would also be on a statin or anti-hypertensive drugs [129]. No effect on conjugated dienes, thiobarbituric acid reactive substances (TBARS), or susceptibility of LDL-C or HDL-C to oxidation was seen post supplementation [129]. The increase seen in erythrocyte GSH, a naturally occurring antioxidant, is probably due to the low GSH found in this group before supplementation \( (0.5 \pm 0.7 \, \text{nmol/mg protein}) \), as the normal range for erythrocyte GSH is between 745 and 1473 \( \mu \text{mol/l} \) in healthy individuals aged 12–69 years [130].

Nuttall et al.’s study of nine Type 2 DM subjects included the most advanced age cohort and one of two cross-over studies under review here, with 500 mg vitamin C and 400IU vitamin E taken during the first supplementation period and 1000 mg vitamin C and 800IU vitamin E taken during the second period [131]. The study was not placebo controlled [131]. With the exception of plasma antioxidants, lipid peroxides were the only marker of oxidative stress measured [131]. It is noted here that all subjects had advanced complications, including neuropathy, cardiovascular complications, and cerebrovascular disease, and the subjects were taking sulphonylureas, and/or metformin, and insulin, although no subjects were taking lipid-lowering therapy [131]. A bigger decrease \( (p < 0.01) \) in lipid peroxides was seen after the first (lower dose) supplementation than the second \( (p < 0.05) \) [131]. The investigators note that the higher doses of vitamins C and E taken during the second supplementation period may have reached the pro-oxidant threshold [131].

Gazis et al. [132] supplemented 48 subjects with Type 2 DM and no vascular complications with 1600IU \( \alpha \)-tocopherol for 8 weeks. This study was the only one to include individual information on the drugs each subject was using to manage diabetes, but no separate statistical analysis was performed on supplementation outcome taking into consideration the medication history of the subjects. No direct biomarkers of oxidative stress were measured and no significant changes in blood flow or vasodilation were seen. In Tessler et al.’s study, 36 subjects with Type 2 DM were randomized into one of three groups, a placebo group, a group taking 0.5 g and a group taking 1 g daily of vitamin C for 12 weeks. DM status was stable in all subjects with HbA1c \( \leq 9\% \) [129]. Conjugated dienes, TBARS, vitamin E content of LDL and HDL lipoproteins and granulocyte levels of vitamin C, GSH and glutathione disulfide (GSSG) were measured [129]. After supplementation (both the 0.5 g per day and 1.0 g per day groups), there was a significant increase \( (p < 0.05) \) in cellular GSH when compared to baseline, although no changes in GSSG were observed [129]. No changes in markers of lipid peroxidation (TBARS and conjugated dienes) were seen [129].

In a supplementation study using mixed tocopherols, 55 Type 2 DM subjects were randomized to take (1) 500 mg \( \alpha \)-tocopherol per day, or (2) a combination of 75 mg \( \alpha \)-
Table 5. Human studies showing increased ox stress and/or depleted antioxidatant status in Type 2 DM.

| Subject characteristics | Biomarkers measured |
|-------------------------|---------------------|
| Type 2 DM subjects and healthy age- and sex-matched controls. Males: |                      |
| Type 2 DM [n = 44], control [n = 33]; Females: Type 2 DM [n = 26], control [n = 26] All subjects had normal hepatic and endocrine functions, with HbA1c 6–7%. All patients were taking oral antidiabetic pills during the study period or the past 3–5 years, with no history of other medications. Diabetic duration 4.0 years. Exclusion criteria – macro- and microangiopathic complication, coronary heart disease or hypertension, life-threatening diseases such as cancer [110] |
| Males: Serum MDA significantly higher in DM compared with controls (0.29 vs. 0.11 pmol/mg protein, p < 0.05). Reduced GSH was decreased in the diabetic group (195.6 vs. 294.8 pmol/mg protein in control, p < 0.05) Females: Similar patterns observed in female groups. MDA concentrations were 0.23 vs. 0.07 pmol/mg protein in controls, p < 0.05. Reduced MDA was 193.9 vs. 250.3 pmol/mg protein in controls, p < 0.05. |
| Type 2 DM patients (HbA1c 7.2%) [n = 44] aged 51–65 years, healthy controls [n = 12]. 23 patients were previously treated with metformin (16 males, 7 females) and 21 treated with SU (16 males, 5 females) [111] |
| Type 2 DM patients’ mean age 52.35 years, mean duration of DM of 6.95 years [n = 64], healthy subjects’ mean age 51.02 years [n = 36] Exclusion criteria – renal, liver, heart diseases [112] |
| Type 2 DM patients mean age 57.2 years [n = 41], HbA1c < 9.1% and control subjects with normal glucose tolerance and no family history of DM, [n = 33] [113] |
| Type 2 DM patients’ mean age 52.35 years, mean duration of DM of 6.95 years [n = 64], healthy subjects’ mean age 51.02 years [n = 36] Exclusion criteria – renal, liver, heart diseases [112] |
| Type 2 DM patients (n = 24) Age-, sex-, and BMI-matched subjects (obese group) [n = 19] Unmatched control group [n = 34] Exclusion criteria – presence of Prader–Willi Syndrome, hypothyroidism, known alcohol or drug abuse, congenital CVD, history of malignancy, use of glucocorticoids, and chronic renal failure or known primary renal disease. None of the participants were taking lipid-lowering drugs [115] |
| Plasma MDA and F₂-isoprostanes significantly lower in the metformin treated group compared with SU-treated group, (MDA, 2.82 ± 3.12 μmol/l, p < 0.05; F₂-isoprostanes: 25.2 ± 3.13 pmol/l, p < 0.05). The HbA1c values were significantly lower in the control group compared with diabetic patients (MDA: 2.51±μmol/l, F₂-isoprostanes: 17.2 pg/ml in the control group). Plasma TAS was lowered in SU-treated group (1.02μmol/l) compared with metformin group (1.31μmol/l) and control (1.45μmol/l), but was higher in control overall compared with diabetic subjects, p < 0.05. SU-treated subjects had the lowest blood total H (590pmol/l) which was significantly lower than the metformin group (819pmol/l) and the control (980μmol/l), p < 0.05. |
| Type 2 DM patients [n = 38] and 36 healthy age-matched controls [n = 36] Subjects not taking antioxidant supplements [114] |
| Type 2 DM patients (n = 24) Age-, sex-, and BMI-matched subjects (obese group) [n = 19] Unmatched control group [n = 34] Exclusion criteria – presence of Prader–Willi Syndrome, hypothyroidism, known alcohol or drug abuse, congenital CVD, history of malignancy, use of glucocorticoids, and chronic renal failure or known primary renal disease. None of the participants were taking lipid-lowering drugs [115] |
| Type 2 DM subjects (mean duration of diabetes: 8.5 years HbA1c ~7.1%) [n = 26] 52 age-matched healthy control subjects [n = 52] All Type 2 DM patients were free of microangiopathy. Exclusion criteria – smoking, inflammatory diseases, known myocardial infarction, stroke. *DM subjects were on with diet and exercise, 18 subjects were on oral hypoglycemic agents [116] |
| Type 2 DM patients (n = 33) without diabetic complications and 27 with diabetic retinopathy, of which 21 were classified as non-proliferative diabetic retinopathy, 6 were proliferative diabetic retinopathy) [n = 60 in total] Healthy, age-matched control subjects [n = 32] Exclusion criteria – acute and chronic infections, fever, malignancy, acute, and chronic nephritis, cirrhosis, and congestive heart failure. All patients were treated with insulin only [117] |
| Type 2 DM subjects (normotensive, treated with only insulin, without diabetic complications, HbA1c ~7.67%) [n = 60] Age-matched healthy controls [n = 60] Exclusion criteria – smoking, oral hypoglycemic agents or other antioxidant therapy [118] |
| Type 2 DM patients (HbA1c ~12.5%) [n = 55] Healthy control subjects [n = 40] All patients were treated with oral hypoglycemic agents, and were not taking any other medications or vitamin supplements [119] |
| Type 2 DM subjects (normotensive, treated with only insulin, without diabetic complications, HbA1c ~7.67%) [n = 60] Age-matched healthy controls [n = 60] Exclusion criteria – smoking, oral hypoglycemic agents or other antioxidant therapy [118] |
| Type 2 DM patients (HbA1c ~12.5%) [n = 55] Healthy control subjects [n = 40] All patients were treated with oral hypoglycemic agents, and were not taking any other medications or vitamin supplements [119] |
| Type 2 DM patients (n = 24) Age-, sex-, and BMI-matched subjects (obese group) [n = 19] Unmatched control group [n = 34] Exclusion criteria – presence of Prader–Willi Syndrome, hypothyroidism, known alcohol or drug abuse, congenital CVD, history of malignancy, use of glucocorticoids, and chronic renal failure or known primary renal disease. None of the participants were taking lipid-lowering drugs [115] |
tocopherol, 315 mg γ-tocopherol, and 110 mg of δ-tocopherol, or (3) placebo for a duration of 6 weeks [133]. Plasma and urinary F₂-isoprostanes and erythrocyte SOD and glutathione peroxidase (GPx) were measured at baseline and at the completion of the supplementation period [133]. Treatment with either α-tocopherol or the mixed tocopherols significantly decreased plasma F₂-isoprostanes when compared with the placebo group. (p < 0.001), although neither treatment affected urinary F₂-isoprostanes [133]. There were no changes in SOD and GPx post supplementation of either α-tocopherol or mixed tocopherols [133]. Diabetes status in this population was well controlled, with mean HbA1c at around 6.6% [133].

In a study by Ble-Castillo et al., Type 2 DM subjects were randomized to receive 800IU α-tocopherol per day (n = 13) or placebo (n = 21) for 6 weeks [134]. Subjects on insulin, hormonal therapy, antioxidant supplements, smokers, and with hypertensive were excluded [134]. The investigators reported a 46% reduction in erythrocyte MDA and a significant increase (p < 0.001) in serum total antioxidant in the α-tocopherol group post supplementation when compared to baseline [134]. These results are in conflict with other studies investigating the effect of antioxidant supplementation on oxidative stress markers in subjects with Type 2 DM and may be unreliable. The actual concentrations of serum TAS and the erythrocyte MDA were not given, and the results are simply shown in graphical form. In addition, the serum-TAS concentrations reported are lower than the range given by the manufacturers of the kit (Randox) by a factor of a thousand.

In summary, vitamin C and vitamin E are the most popular antioxidants used in supplementation studies in subjects with Type 2 DM. The supplementation period of studies reviewed here is between 3 and 12 weeks. Ascorbic acid depletion-repletion studies have shown that both plasma and intracellular ascorbic acid will reach saturation at doses of 500 mg per day within about 40 days of supplementation, which is around 6 weeks [135]. This could mean plasma and tissue concentrations of ascorbic acid would not have reached optimal levels for that dose in studies with a supplementation period of less than 6 weeks, although the doses used are many fold higher than the recommended daily amount (RDA) of up to 90 mg [136]. All studies using vitamin E also supplemented subjects with much more than the RDA of 22.5IU (15 mg) [137].

Although all studies reviewed in this section (and summarized in Table 6) are antioxidant supplementation studies, the study population are diverse. Ages ranged from 40 to 77 years, and while some used subjects who were comparatively complication-free, subjects used in other studies had suffered serious micro- and macro-vascular complications [6,131].

With all these differences in age, methods of DM management and inclusion/exclusion criteria in the study populations and outcomes assessed to determine benefit, it is very difficult to compare results across studies. Most investigators excluded subjects who were already taking the supplement in question, while some asked subjects to stop taking any type of antioxidant supplements weeks prior to the start of the study [129,134]. Gaede et al. [6] asked their subjects to stop taking vitamin C and E and ACE-inhibitors 8 weeks prior to the start of the supplementation period, although hypoglycemic drugs continued to be used. However, Levine et al. did not specify such exclusion criteria [136]. It is noted here that the subjects with Type 2 DM in Darko et al.’s study were not deficient in vitamin C, with mean plasma concentrations of 58 ± 6 µmol/l, which is higher than the normal range of 23–50 µmol [140,143]. The fact that the subjects were not deficient in vitamin C may have contributed to the lack of benefit seen in the only biomarker of oxidative stress measured, plasma F₂-isoprostanes.

Although some studies collected information on the polypharmacy used in the management of Type 2 DM in the subjects studied, none of the investigators analyzes data taking into account the medication of the subjects.

With the exception of one study, it is clear that supplementing Type 2 DM subjects with oral antioxidants will not further decrease oxidative stress, as seen by the oxidative stress markers measured. It is noted though that none of the above studies looked at subjects who were on oral hypoglycemics, insulin, or statins separately from those subjects who were not taking any of these medications.

In the only antioxidant supplementation study involving patients with Type 1 DM, Beckman et al. gave, vitamin C (1 g) and vitamin E (800IU), per day, or placebo to Type 1 DM subjects (n = 26), Type 2 DM subjects (n = 23), and healthy matched controls (n = 45) for 6 months [144]. In those with Type 1 DM, antioxidant supplementation increased endothelium-dependent vasodilation (p = 0.023) when compared to baseline, whereas no such effect was seen in those with Type 2 DM [144]. Although no mention was given as to the number of Type 2 DM subjects who were on oral hypoglycemics, it is surmised that the majority of them would be on polypharmacy, whereas the Type 1 DM subjects would most likely be solely on injected insulin therapy. A search of the literature did not result in any studies which have investigated any antioxidant effect of insulin. Beckman et al. did note, however, that at baseline, the Type 1 DM subjects were younger, had lower total cholesterol (TC), glucose, and mean arterial pressure than the Type 2 DM subjects [144].

It cannot be discounted, therefore, that differences in age, cholesterol, and glucose concentrations contributed to the difference seen in the result, but it is proposed here that it is possible that the Type 2 DM subjects who are likely to be on oral hypoglycemics and statins would have reached antioxidant-effect-saturation. This does not mean that their tissues were saturated with antioxidants, but it might be feasible that, even if the tissue antioxidant concentration was increased, no further benefits will be seen. This is shown clearly in two controlled studies, De Caterina et al. [59] and Pereira et al. [61], summarized in Table 4, where no further oxidative stress-lowering effects were seen when vitamin E was added to the regimen of subjects taking statins.

It should be taken into consideration also that in health, the balance between reactive species and antioxidant defenses lies slightly in favor of the reactive species so that they are able to fulfill their biological roles and artificially increasing the antioxidant concentration may possibly result in deleterious effects [145].

**Drugs used in the management of Type 2 diabetes and their mechanisms of antioxidant action**

Sulfonylureas stimulate insulin release by binding to the sulfonylurea receptor, a subunit of the ATP-dependent K⁺ (K₅ ATP)
Table 6. Antioxidant supplementation studies in Type 2 DM subjects.

| Subjects characteristics/ test material | Study description | Outcome/biomarkers investigated | Information on existing treatment |
|-----------------------------------------|-------------------|---------------------------------|----------------------------------|
| Type 2 DM subjects meeting the following criteria: DM onset after 35 years of age, at least 5-year disease without insulin use, FPG ≥ 7.8 mmol/l, BMI < 33 kg/m², serum creatinine < 2.0 mg/dl. Exclusion criteria included: history of ketoacidosis, onset of diabetes before age 35, smoking, use of vitamin supplements, treatment with glucocorticoids, thyroid hormone, lipid-lowering agents, or other drugs known to affect serum lipids, urine protein excretion > 250 mg/d and serum α-tocopherol levels > 28 μmol/l [138]. | All subjects supplemented with RRR-α-tocopherol (1200 IU/day), following a 2-month washout. (1) Type 2 DM subjects without macrovascular complications [n = 24] (2) Type 2 DM patients with macrovascular complications [n = 23] (3) Age-, sex-, and BMI-matched healthy control subjects [n = 25]. Treatment duration, 3 months. | hsCRP decreased in all three groups after supplementation compared to both baseline and placebo group (p < 0.02). IL-6 concentrations significantly decreased following supplementation in all three groups, p < 0.02. Compared to matched controls, group 2 showed significantly elevated hsCRP, all DM patients had increased levels of monocyte IL-6. No information given | |
| Type 2 DM subjects and healthy controls. Exclusion criteria included smoking, use of antioxidant supplements, hypolipidemic drugs, beta-blockers, or NSAID, renal or liver dysfunction, and alcohol consumption > 1 oz/day [139]. | Subjects randomized to (1) 1600 IU α-tocopherol, [n = 48]. (2) Placebo, [n = 21]. Treatment duration, 8 weeks. | α-tocopherol treatment increased plasma vitamin E from 28.2 to 65.9 μmol/l (p < 0.01). No significant changes in basal blood flow or on vasodilation to low or high doses of the endothelium-independent vasodilator sodium nitroprusside or the endothelium-dependent vasodilators acetylcholine and bradykinin, were seen in either group. Plasma ascorbic acid increased from 58.0 vs. 11.6 μmol/l, p < 0.01; 8.0 vs. 11.6 μmol/l, p < 0.01 (high). No information given | |
| Type 2 DM patients with urinary albumin excretion rate between 30 and 300 mg/24 h. Exclusion criteria included: SBP > 200 mmHg, DBP > 110 mmHg, GFR < 40 ml/min/1.73 m², prior MI or congestive heart failure. Treatment with ACE-inhibitors (n = 28), vitamin E and C supplements (n = 3) was stopped and BP was strictly monitored and controlled at < 180 mmHg at least 8 weeks before study commenced [6]. | Subjects randomized to (1) Vitamin C (1500 mg/day) [n = 18] (2) Placebo [n = 17]. Treatment duration, 3 weeks. | Cross-over study [n = 9], first treatment 500 mg vitamin C and 4000 IU vitamin E/day Treatment duration, 4 weeks; 4-week washout period. Second treatment – 1000 mg vitamin C and 800 IU vitamin E/day Treatment duration, 4 weeks. | 48 subjects were either treated with diet alone [n = 17], sulphonylureas [n = 20], metformin [n = 5], or both [n = 6]. Metformin, sulphonylureas, ACE inhibitors, diuretics, calcium channel blockers Individual medication details are not given, but subjects were on sulphonylureas and/or metformin or insulin, or diet alone. |
Table 6. Continued.

| Subjects characteristics/ test material | Study description | Outcome/biomarkers investigated | Information on existing treatment |
|-----------------------------------------|-------------------|---------------------------------|----------------------------------|
| renal or liver dysfunction poorly accessible veins and alcohol consumption [134] | Randomized in a double-blind, placebo-controlled trial to (1) 500 mg RRR-α-tocopherol/day [n = 19] (2) 500 mg mixed tocopherols (60% γ-, 25% δ- and 15% α-tocopherol/day [n = 20] (3) Placebo [n = 19] Treatment duration, 6 weeks *3-week washout period prior to the study. Subjects ceased all vitamin, antioxidant/ fish oil supplements | erythrocyte CuZn-SOD activity (from 1083 to 876.4 U/g, p < 0.001) seen in the treatment group | Treatment with α-tocopherol and mixed tocopherols significantly increased blood pressure and heart rate versus placebo. There was no significant difference between the two treatment groups. Plasma total F2-isoprostane significantly reduced following either treatment versus placebo, but urinary F2-isoprostane not affected. |
| Type 2 DM patients Exclusion criteria included body mass index (in kg/m²) > 35; use of insulin, nonsteroidal anti-inflammatory drugs, or nitrate medication; smoking; use of vitamin E supplements; any recent (in previous 6mo) coronary or cerebrovascular event; impaired renal function (serum creatinine > 110 μmol/l for men and > 100 μmol/l for women); and alcohol intake > 40 g/day for men and > 30 g/d for women. All volunteers ceased consuming any vitamin, antioxidant, or fish oil supplements for ≥ 3wk before study entry [133] | Subjects randomized to (1) 500 mg RRR-α-tocopherol/day [n = 18] (2) 500 mg mixed tocopherols (75 mg α-, 315 mg γ- and 110 mg δ-tocopherol) [n = 19] (3) Placebo [n = 18] Treatment duration, 6 weeks *3-week washout period prior to the study. Subjects ceased all vitamin, antioxidant/ fish oil supplements | Plasma total F2-isoprostane significantly (P = 0.001) reduced following either treatment versus placebo, but urinary F2-isoprostane not affected. No significant changes seen in erythrocyte SOD and GPx after any supplementation regimen. | Antihypertensives, oral hypoglycemics, aspirin, lipid lowering therapy, BP treatment |
| Type 2 DM patients with diabetes for ≥1 year and no clinical evidence of overt vascular diseases, acute or chronic inflammatory diseases [141] | Subjects randomized to (1) Placebo [n = 12] (2) Vitamin C (0.5 g/day) [n = 12] (3) Vitamin C (1 g/day) [n = 12] Treatment duration, 12 weeks | Significant increase in cellular GSH was observed (0.60 vs. 0.33 nmol/mg protein in the placebo group, p < 0.01) in patients on 0.5 g vitamin C/day. Significant increases in cellular GSH (0.93 vs. 0.33 nmol/mg proteins in the placebo, p < 0.01), seen in those on 1.0 g vitamin C/day. Vitamin C had no effect on the vitamin E content of HDL in any group. At week 12, no significant difference was seen in lipid peroxidation/oxidative stress markers (conjugated dienes, TBARS) and susceptibility of LDL and HDL to oxidation in the two treatment groups compared to placebo. MDA significantly decreased at fasting (p = 0.006) and postprandial states (p < 0.001) in vitamin C group, compared to placebo group. No significant differences were seen in fasting and postprandial lipid profile. | Percentage of participants on oral hypoglycemics, (58%), antihypertensives, (51%), lipid-lowering drugs, (53%), aspirin, (38%). |
| Type 2 DM patients with no history of other chronic diseases, kidney stones, hyperparathyroidism, pregnancy and lactation, current insulin treatment and treatment for weight reduction [142] | Subjects randomized to (1) Vitamin C (1 g/day) [n = 14] (2) Acetate cellulose placebo 1000 mg/day, [n = 13] Treatment period, 6 weeks | Tg decreased significantly in vitamin E group (212 ± 85 mg/dl), compared to placebo group (254 ± 170 mg/dl). No significant differences were seen in serum fasting glucose, HbA1c and β-cell function after vitamin E supplementation, compared to placebo group. | Individual medication details are not given, but subjects on glibenclamide, metformin or insulin |

channel complex on the cell membrane of pancreatic β-cells, causing an increase in intracellular calcium, which in turn increases the secretion of pro-insulin. Gliclazide is known to be a free-radical scavenger, and an in vivo study of 44 Type 2 DM subjects taking gliclazide for 10 months resulted in a decrease in 8-isoprostanes, a marker of lipid oxidation, and an increase in the total antioxidant capacity and SOD [146,147]. Other sulfonylureas, including glipizide tolazamide, and glibenclamide do not exhibit antioxidant activity [148].

Thiazolidinediones (TZD) work to decrease insulin resistance by binding to peroxisome proliferator-activated receptors gamma (PPARγ). These receptor molecules are found inside the cell nucleus, and when activated migrate to DNA and activate the transcription of a number of genes, including SOD and catalase [149–151]. In addition to being able to indirectly upregulate antioxidant genes, certain TZD, for example, troglitazone, may be able to exert direct antioxidant effects through a side chain which resembles α-tocopherol [152,153]. All TZDs exhibit intracellular antioxidant properties as they are able to reduce NO production through the transrepression of iNOS [153,154].
Biganuicde decreases hepatic glucose output and increase the uptake of glucose by skeletal muscle. Metformin exerts its antioxidant effect through mechanisms other than direct radical scavenging [155]. In vitro experiments have shown that metformin is able to prevent the formation of advanced glycation end-products when albumin was incubated in the presence of dicarbonyl compounds [156]. In vitro experiments with endothelial cells grown in hyperglycemic (10 mmol) conditions have shown that co-incubating the cells with metformin (20 mmol) can inhibit the formation of NAD(P)H oxidase, and therefore, decrease production of hydrogen peroxide [157]. Co-incubation with metformin also leads to an increase in the activity of catalase in both euglycemic and hyperglycemic conditions [157].

Alpha-glucosidase inhibitors slow the digestion of starch in the small intestine so that glucose can enter the bloodstream more slowly. Alpha-glucosidase inhibitors in use include acarbose and miglitol. To date, no antioxidant effects have been reported in these drugs.

Meglitinides, including repaglinide and nateglinide, bind to a $K_{ATP}$ channel on the cell membrane of pancreatic $\beta$-cells in a similar manner to sulfonylureas but at a separate binding site. Meglitinides have not been shown to possess any antioxidant properties.

Statins act by competitively inhibiting HMG-CoA reductase and decreasing cholesterol synthesis in the liver. By inhibiting Rac isoprenylation, statins can lead to a reduction in NAD(P)H oxidase and generation of reactive oxygen species [158,159]. In an animal study, simvastatin was able to decrease the formation of superoxide by inhibiting Rac1, a signaling protein involved in cell growth, cell cycle, cell–cell adhesion, and the activation of protein kinases [160].

Pleiotropic effects of diabetic polypharmacy and their possible confounding effects on observational and supplementation trials of antioxidants

In vitro, animal and human studies have been conducted on the pleiotropic, and in particular, the antioxidant effects of statins and hypoglycemic drugs. Tables 1 and 2 summarize the data on statins and hypoglycemic drugs, concentrating on studies which have looked at changes in antioxidant/oxidative stress balance. From the controlled studies of statin ingestion with antioxidant vitamins, some insight into whether these pharmaceuticals are co-operators, confounders, or concealers of oral antioxidants taken in supplement form is offered.

Conclusions

Evidence that Type 2 DM subjects are in a state of oxidative stress is unequivocal. Short-term supplementation with antioxidant vitamins C and/or E has not further decreased oxidative stress markers in Type 2 DM subjects. That is not to say that antioxidant vitamin supplementation has no role in Type 2 DM, but the effects of these antioxidants may be concealed or confounded by the cocktail of medications already being taken by the patient, and pharmacological agents themselves may have strong antioxidant effects. Further study is required to ascertain if oral antioxidant vitamin supplementation can be a cheap and safe method which can benefit those Type 2 DM subjects whose diabetes, hypertension, and hypercholesterolemia is being controlled by diet alone.

Acknowledgements

We would like to thank Professor Iris Benzie, Chair Professor of Biomedical Science at the Hong Kong Polytechnic University for her contribution to the ideas discussed in this manuscript and Professor Brian Tomlinson, Department of Medicine & Therapeutics at The Chinese University of Hong Kong for the provision of the drugs used to test antioxidant properties. Thanks also go to Dr. Diane Tran, Honorary Clinical Assistant Professor, Department of Anesthesiology, The University of Hong Kong for her help in proofreading this article. The authors alone are responsible for the content and writing of the paper.

Disclosure statement

No potential conflict of interest was reported by the authors.

Notes on contributors

Mr Cyrus K. HO is currently an assistant research officer at the University of Hong Kong, and is working on precision medicine in the area of pain and anesthesia.

Mr Siu Wai CHOI works in the field of antioxidants and oxidative stress.

References

[1] Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus – present and future perspectives. Nat Rev Endocrinol. 2012;8(4):228–336.
[2] Skrha J. Diabetes mellitus – a global pandemic. Keynote lecture presented at: the Wonca conference; 2013 June; Prague. Eur J Gen Pract. 2014;20(1):65–68.
[3] van Dieren S, Beulens JW, van der Schouw YT, et al. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17(Suppl 1):S3–58.
[4] Ramachandran A, Snehalatha C, Shetty AS, et al. Trends in prevalence of diabetes in Asian countries. World J Diabetes. 2012;3(6):110–117.
[5] Kemer W, Bruckel J. German diabetes A. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes. 2014;122(7):384–386.
[6] Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591.
[7] Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009;203(2):325–330.
[8] Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coronary Artery Dis. 2004;15(5):251–258.
[9] Elsaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin. 2002;18(5):269–276.
[10] Franke SI, Muller LL, Santos MC, et al. Vitamin C intake reduces the cytotoxicity associated with hyperglycemia in prediabetes and type 2 diabetes. BioMed Res Int. 2013;2013:896356.
[11] Lam CS, Benzie IF, Choi SW, et al. Relationships among diabetic retinopathy, antioxidants, and glycemic control. Optom Vis Sci. 2011;88(2):251–256.
[12] Prentki M, Nolan CJ. Islet $\beta$ cell failure in type 2 diabetes. J Clin Invest. 2006;116(7):1802–1812.
[13] American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl1):S6–69.
[14] Shin D, Cho YM, Lee S, et al. Pharmacokinetic and pharmacodynamic interaction between gemiglitpin and metformin in healthy subjects. Clin Drug Investig. 2014;34(6):383–393.
[15] Dhawan S, Singh B, Garg SK, et al. Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. Clin Pharmacokinet. 2006;45(3):317–324.
De Caterina R, Cipollone F, Filardo FP, et al. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation. 2002;106(20):2543–2549.

Jula A, Marniemi J, Huupponen R, et al. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA. 2002;287(5):598–605.

Pereira EC, Bertolami MC, Faludi AA, et al. Antioxidant effect of simvastatin is not enhanced by its association with alpha-tocopherol in hypercholesterolemic patients. Free Radic Biol Med. 2004;37(9):1440–1448.

Shin MJ, Cho EY, Jang Y, et al. A beneficial effect of simvastatin on DNA damage in 24 T allele of the NADPH oxidase p22phox in hypercholesterolemic patients. Clin Chim Acta. 2003;360(1–3):167–170.

Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003;289(13):1673–1680.

Manfredini V, Biancini GB, Vanzin CS, et al. Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients. Cell Biochem Funct. 2010;28(5):360–366.

Oranje WA, Sels JP, Rondas-Colbers GJ, et al. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta. 2001;311(1–2):91–94.

Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003;289(13):1673–1680.

Save V, Patil N, Moulik N, et al. Effect of atorvastatin on type 2 diabetic dyslipidemia. J Cardiovasc Pharmacol Ther. 2006;11(4):262–270.

Tousoulis D, Antoniades C, Vasiiladou C, et al. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmetrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Heart. 2007;93(2):244–246.

Cangemi R, Loffredo L, Carnevale R, et al. Early decrease of oxidative stress by atorvastatin in hypercholesterolemic patients: effect on circulating vitamin E. Eur Heart J. 2008;29(1):54–62.

Usharani P, Mateen AA, Naidu MU, et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D. 2008;9(4):243–250.

Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q10 improves further effect of vitamin E. Circulation. 2002;106(20):2543–2549.

Vecchione C, Gentile MT, Arenti A, et al. A novel mechanism of action for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here? J Intern Med. 2015;277(2):235–247.

Balogh Z, Seres I, Harangi M, et al. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab. 2001;27(5 Pt 1):504–510.

Koh KK, Son JW, Ahn JY, et al. Simvastatin combined with ramipril reduces intracellular production of reactive oxygen species in aortic endothelial cells. Metab Clin Exp. 2005;54(6):829–834.

Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of type 2 diabetic patients. Diabetes Res Clin Pract. 2006;71(1):52–58.

Werpa JP, Cavalca V, Veglia F, et al. A new compound-specific pleiotropic effect of statins: modification of plasma gamma-tocopherol levels. Atherosclerosis. 2007;193(1):229–233.

Cangemi R, Loffredo L, Carnevale R, et al. Statins enhance circulating vitamin E. Int J Cardiol. 2008;123(2):172–174.

Hogue JC, Lamarche B, Tremblay AJ, et al. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metab Clin Exp. 2008;57(3):380–386.

Koskali M, Eren MA, Turan MN, et al. The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. Eur J Intern Med. 2011;22(3):249–253.

Khanha HD, Sinha MK, Khanna S, et al. Oxidative stress in hypertensive association with antihypertensive treatment. Indian J Physiol Pharmacol. 2008;52(3):283–287.

Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121(1):110–122.

Rachmani R, Lidor M, Brosh D, et al. Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: a randomized cross-over study. Diabetes Res Clin Pract. 2000;48(2):139–145.

Baykal Y, Yilmaz MI, Celik T, et al. Effects of antiphenotypic agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress. J Hypertens. 2003;21(6):1207–1211.

Bank AJ, Kelly AS, Thelen AM, et al. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens. 2007;20(7):777–783.

Sawada T, Takahashi T, Yamada H, et al. Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events. J Hum Hypertens. 2009;23(3):188–195.

Lim S, Barter P. Antioxidant effects of statins in the management of cardiometabolic disorders. J Atheroscler Thromb. 2014;21(10):997–1010.

Mason RP. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol. 2006;98(11):127–139.

Fracimero E, Buttari B, Sasso L, et al. Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin. Curr Top Med Chem. 2014;14(22):2542–2551.

Ali F, Hamdulay SS, Kinderlerer AR, et al. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost. 2007;5(7):2537–2546.

Vecchione C, Gentile MT, Arenti A, et al. A novel mechanism of action for statins against diabetes-induced oxidative stress. Diabetologia. 2007;50(4):874–880.

Keil A, Tellis C, Liberopoulos E, et al. Effect of switch to the highest dose of rosuvastatin versus add-on statin fenofibrate versus add-on statin nicotinic acid/aripiprant on oxidative stress markers in patients with mixed dyslipidemia. Cardiovasc Ther. 2014;32(4):139–146.

Emani-Riedmaier A, Schaffrath E, Nies AT, et al. Statin-like medicine for the use of antioxidant medication in treatment of type II diabetes and cancer: where do we go from here? J Atheroscler Thromb. 2015;22(7):235–247.

Violet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2012;122(6):253–270.

Bonnefont-Rousselot D, Raji B, Walrand S, et al. Intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metab Clin Exp. 2003;52(5):586–598.

Ouslimani N, Peynet J, Bonnefont-Rousselot D, et al. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metab Clin Exp. 2005;54(6):829–834.

Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of type 2 diabetic patients. Diabetes Res Clin Pract. 2006;71(1):52–58.
mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol. 2004;286(2):H742–H748.

[101] Boekholt SM, Meuwese MC, Day NE, et al. Plasma concentrations of ascorbic acid and C-reactive protein, and risk of future coronary artery disease, in apparently healthy men and women: the EPIC-Norfolk prospective population study. Br J Nutr. 2006;96(3):516–522.

[102] Hirsch IB, Evans TC, Gaster B. Insulin treatment for type 2 diabetes. JAMA. 1999;280(15):1524–1526.

[103] Ma SW, Benzie IF, Chu TT, et al. Effect of Panax ginseng supplementation on biomarkers of glucose tolerance, antioxidant status and oxidative stress in type 2 diabetic subjects: results of a placebo-controlled human intervention trial. Diabetes Obes Metab. 2008;10(11):1125–1127.

[104] Reddy VS, Agrawal P, Sethi S, et al. Associations of FPG, A1C and disease duration with protein markers of oxidative damage and antioxidative defense in type 2 diabetes and diabetic retinopathy. Eye. 2015;29(12):1585–1593.

[105] Sargeant LA, Wareham NJ, Bingham S, et al. Vitamin C and hyperglycaemia in the European Prospective Investigation into Cancer – Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care. 2002;25(6):726–732.

[106] Sgherrouchi N, Drai J, Bannier E, et al. Oxidative stress parameters in type I, type II and insulin-treated type 2 diabetes mellitus; insulin treatment efficiency. Clin Chim Acta. 2003;321(1–2):89–96.

[107] Yamada H, Yamada K, Waki M, et al. Lymphocyte and plasma vitamin C levels in type 2 diabetic patients with and without diabetes complications. Diabetes Care. 2004;27(10):2491–2492.

[108] Jiménez-Osorio AS, Pizaño A, González-Reyes S, et al. Nrf2 and redox status in prediabetic and diabetic patients. Int J Mol Sci. 2014;15(11):20290–20305.

[109] Al-Aubaidy HA, Jelinké HF. Oxidative DNA damage: antioxidant response in postprandial hyperglycemia in type 2 diabetes mellitus. Br J Diab Vasc Dis. 2011;11:87–91.

[110] Mahboob M, Rahman MF, Groper P. Serum lipid peroxidation and antioxidant enzyme levels in male and female diabetic patients. Singapore Med J. 2005;46(7):322–324.

[111] Faure P, Wiernsperger N, Polge C, et al. Impairment of the antioxidant vitamin C pharmacokinetics in patients with diabetes: protective effects of metformin. Clin Sci. 2008;114(3):251–256.

[112] Turk KM, Sevinski A, Camci C, et al. Plasma lipid peroxidation products and antioxidant enzyme activities in patients with type 2 diabetes mellitus. Acta Diabetol. 2002;39(3):117–122.

[113] Shin CS, Moon BS, Park KS, et al. Serum 8-hydroxy-quinone levels are increased in diabetic patients. Diabetes Care. 2001;24(4):733–737.

[114] Rehman A, Nouroz-Zadeh J, Moller W, et al. Increased oxidative damage to all DNA bases in patients with type II diabetes mellitus. FEMS Lett. 1999;448(1):120–122.

[115] Stringer DM, Sellers EA, Burr LL, et al. Altered plasma adipokines and markers of oxidative stress suggest increased risk of cardiovascular disease in First Nation youth with obesity or type 2 diabetes mellitus. Pediatr Diabetes. 2009;10(4):269–277.

[116] Nakaniishi S, Suzuki G, Kusunoki Y, et al. Increasing high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H oxidase activation. Diabetes. 2003;52(11):2795–2804.

[117] Pan HZ, Zhang H, Chang D, et al. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol. 2008;92(10):1346–1351.

[118] Kalaiyanam KN, Dharmalingam M, Marcus SR. Lipid peroxidation in type 2 diabetes mellitus. Int J Diab Dev Ctries. 2006;26(1):30–32.

[119] Ramakrishna V, Jaikilli R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 2008;45(1):41–46.

[120] Giacci A, Sorice G, Muscoqiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment. Nutr Metab Cardiovasc Dis. 2009;19(5):365–377.

[121] Monnier L, Colette C, Owens DR. Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes Metab Res Rev. 2009;25(5):393–402.

[122] Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H oxidase activation. Diabetes. 2003;52(11):2795–2804.

[123] Choi SW, Benzie IF, Ma SW, et al. Acute hyperglycaemia and oxidative stress: direct cause and effect? Free Radic Biol Med. 2008;44(7):1217–1231.

[124] Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005;19(3):178–181.

[125] Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–1070.

[126] Matouff KA, Budin SB, Hamid ZA, et al. The role of oxidative stress and antioxidants in diabetic complications. Sultan Qaboos Univ Med J. 2012;12(1):5–18.

[127] Ward NC, Wu JH, Clarke MW, et al. The effect of vitamin E on blood pressure in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Hypertens. 2007;25(1):227–234.

[128] Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidant stress: an overview. Curr Protoc Toxicol. 2005;105:510–523.

[129] Tessier DM, Khalil A, Trottier L, et al. Effects of vitamin C supplementation on antioxidants and lipid peroxidation markers in elderly subjects with type 2 diabetes. Arch Gerontol Geriatr. 2009;48(1):67–72.

[130] Erden-Inal M, Sunal E, Kanbak G. Age-related changes in the glutathione redox system. Cell Biochem Funct. 2002;20(1):61–66.

[131] Beat-Castillo JL, Carmona-Diaz E, Mendez JD, et al. Effect of alpha-tocopherol and mixed tocopherol supplementation on markers of oxidative stress and inflammation in type 2 diabetes. Clin Chem. 2007;53(3):511–519.

[132] Ble-Castillo JL, Carmona-Diaz E, Mendez JD, et al. Effect of alpha-tocopherol on the metabolic control and oxidative stress in female type 2 diabetics. Biomed Pharmacother. 2005;59(6):290–295.

[133] Levine M, Conny-Cantilena C, Yet al W. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. PNAS. 1996;93(8):3704–3709.

[134] Levine M, Rumsey SC, Daruvala R, et al. Criteria and recommendations for vitamin C intake. JAMA. 1999;281(15):1415–1423.

[135] Horwitt MK. Critique of the requirement for vitamin E. Am J Clin Nutr. 2001;73(6):1003–1005.

[136] Anderson JW, Gowri MS, Turner J, et al. Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabetes mellitus. J Am Coll Nutr. 1999;18(5):451–461.

[137] Devaraj S, Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med. 2000;29(8):790–792.

[138] Darko D, Dornhorst A, Kelly FJ, et al. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in Type II diabetes. Clin Sci. 2002;103(4):339–344.

[139] Mazzolou Z, Hejazi N, Dabbaghmanesh MH, et al. Effect of vitamin C supplementation on postprandial oxidative stress and lipid profile in type 2 diabetic patients. Pakistan J Biol Sci. PJBS. 2011;14(19):900–904.

[140] Shab-Bidar S, Mazzolou Z, Mousavi-ShiraziF Z. Daily vitamin E supplementation does not improve metabolic and glycemic control in type 2 diabetic patients: a double blinded randomized controlled trial. J Diabetes. 2013;5(1):57–58.

[141] Lykkefseldt J, Poulsen HE. Is vitamin C supplementation beneficial? Lessons learned from randomised controlled trials. Br J Nutr. 2010;103(9):1251–1259.

[142] Beckman JA, Goldfine AB, Gordon MB, et al. Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol. 2003;285(6):H2392–H2398.

[143] Evans P, Halliwell B. Micronutrients: oxidant/antioxidant status. Br J Nutr. 2001;85(Suppl2):S67–74.
McGavin JK, Perry CM, Goa KL. Gliclazide modified release. Drugs. 2002;62(9):1357–1364.

O’Brien RC, Luo M, Balazs N, et al. In vitro and in vivo antioxidant properties of gliclazide. J Diab Compl. 2000;14(4):201–206.

Prato S D, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metab Clin Exp. 2006;55(5Suppl1):S20–S27.

Girnun GD, Domann FE, Moore SA, et al. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol. 2002;16(12):2793–2801.

Inoue I, Goto S, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+;Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metab Clin Exp. 2001;50(1):3–11.

Khoo NK, Hebbar S, Zhao W, et al. Differential activation of catalase expression and activity by PPAR agonists: implications for astrocyte protection in anti-glioma therapy. Redox Biol. 2013;1:70–79.

Chung CJ, Pu YS, Chen YT, et al. Protective effects of plasma alpha-tocopherols on the risk of inorganic arsenic-related urothelial carcinoma. Sci Total Environ. 2011;409(6):1039–1045.

Galli A, Mello T, Ceni E, et al. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs. 2006;15(9):1039–1049.

Ros RD, Assaloni R, Ceriello A. The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet Med. 2004;21(11):1249–1252.

Khouri H, Collin F, Bonnefont-Rousselot D, et al. Radical-induced oxidation of metformin. Eur J Biochem. 2004;271(23–24):4745–4752.

Ruggiero-Lopez D, Lecomte M, Moinet G, et al. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol. 1999;58(11):1765–1773.

Gallo A, Ceolotto G, Pinton P, et al. Metformin prevents glucose-induced protein kinase C-beta2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes. 2005;54(4):1123–1131.

Pagano PJ, Chanock SJ, Siwik DA, et al. Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension. 1998;32(2):331–337.

Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22(2):300–305.

Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108(10):1429–1437.